Immunomodulating therapy with rIL-2 and interferon alpha induces in vivo expression of Bcl-2, Fas (APO-1/CD95), and Fas ligand on peripheral lymphocytes (A pilot study)
G. Demir et al., Immunomodulating therapy with rIL-2 and interferon alpha induces in vivo expression of Bcl-2, Fas (APO-1/CD95), and Fas ligand on peripheral lymphocytes (A pilot study), ANTICANC R, 19(4C), 1999, pp. 3517-3520
The first Phase I Trial with a combination of IL-2 and IFN-alpha was publis
hed in 1989. There are still some questions though, concerning the in vivo
effects of this combination on lymphocytes. We designed a prospective pilot
study to evaluate in vivo effects of low dose IL-2 and IFN-alpha combinati
on on expression of Bcl-2, FAS (Apo-1/CD 95), Fas Ligand, IL-2 receptor (CD
25), and HLA-DR on peripheral lymphocytes in patients with advanced renal c
ell carcinoma. After initiation of the immunomodulating therapy, Bcl-2 expr
essing lymphocytes increased significantly on day 3 (p < 0.025), Fas (Apo-1
/CD95) expressing lymphocyte increased significantly on day 5 (p < 0.003),
Fas ligand expressing lymphocytes increased significantly on day 3 (p < 0.0
04), HLA-DR expressing lymphocytes increased significantly on day 5 (p < 0.
003), and IL-2 receptor (CD25) expressing cells increased significantly on
day 5 (p < 0.01). We conclude that immunomodulating therapy induces in vivo
expression of Bcl-2.